Trial Profile

A multicenter, double-blind, randomised, placebo-controlled, parallel-group trial to investigate the efficacy and safety of SPM 927 (200mg/day and 400mg/day) as adjunctive therapy in subjects with partial seizures with or without secondary generalization

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 03 Oct 2017

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

01 Mar 2009 Results published in Epilepsia.
08 Dec 2008 Results of a pooled analysis, which included this trial, were presented at the 62nd Annual Meeting of the American Epilepsy Society.
29 Oct 2005 New trial record.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com